We have seen 0 institutional investors add shares of $INKT stock to their portfolio, and 10 decrease their positions in their most recent quarter.

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com ...

Cash Balance: Increased to $13.4 million from $4.6 million. Net Loss (Q4 2025): $2.6 million or $0.56 per share. Net Loss (Full Year 2025): $12.5 million or $2.93 per share. Operating Cost: Decreased ...

The price trend for MiNK Therapeutics, Inc. (INKT) has been bearish lately and the stock has lost 5.5% over the past week. However, the formation of a hammer chart pattern in its last trading session ...

MiNK Therapeutics, Inc. (NASDAQ:INKT) shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million. What Happened: On ...

MiNK Therapeutics, Inc. (NASDAQ:INKT) stock is trading higher on Friday, with a session volume of 20.2 million compared to the average volume of 7.5 million as per data from Benzinga Pro. The clinical ...

An update from MiNK Therapeutics ( (INKT)) is now available. On December 29, 2025, Robert Kadlec, MD, resigned from the Board of Directors of MiNK Therapeutics, Inc., including all committee roles, ...

Detailed price information for Mink Therapeutics Inc (INKT-Q) from The Globe and Mail including charting and trades.